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ThermotoleranceHeat shock transcription factor 1 (HSF1), themajor regulator of stress response, is frequently activated in cancer
and has an apparent role inmalignant transformation. Herewe analyzed the inﬂuence of the over-expression of a
constitutively active transcriptionally-competent HSF1 mutant form on phenotypes of mouse and human
melanoma cells. We observed that the expression of active HSF1 supported anchorage-independent growth
in vitro, and metastatic spread in the animal model in vivo, although the proliferation rate of cancer cells was
not affected. Furthermore, active HSF1 enhanced cell motility, reduced the adherence of cells to a ﬁbronectin-
coated surface, and affected the actin cytoskeleton. We found that although the expression of active HSF1 did
not affect levels of epithelial-to-mesenchymal transition markers, it caused transcriptional down-regulation of
vinculin, protein involved in cell motility, and adherence. Functional HSF1-binding sites were found in mouse
and human Vcl/VCL genes, indicating a direct role of HSF1 in the regulation of this gene. An apparent association
between HSF1-induced down-regulation of vinculin, increased motility, and a reduced adherence of cells
suggests a possible mechanism of HSF1-mediated enhancement of the metastatic potential of cancer cells.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. IntroductionHeat Shock Transcription Factor 1 (HSF1) is the major regulator of
cellular response to stress, which is activated by various environmental
and pathophysiological stimuli [2]. It is the primary transcriptional
regulator of genes encoding for heat shock proteins (HSPs), which
function asmolecular chaperones and play an important role in the reg-
ulation of protein homeostasis and cell survival during proteotoxic
stress. Moreover, HSPs mediate cytoprotection by the direct inhibition
of key steps of programmed cell death [3]. Beyond the regulation of
HSPs expression, HSF1 binds a broad array of non-HSP genes [18,29,
37]. This property of HSF1 seems to be important in processes associat-
edwith development and growth [1,32], fertility [26,39,42], and longev-
ity [30], which are not related directly with the HSF1-dependent
regulation of HSPs.tion; HS, heat shock; HSF1, heat
Fs,mouse embryonicﬁbroblasts
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. This is an open access article underA high level of HSF1 expression was observed in a broad range
of cancer cell lines and human tumors including colorectal cancer,
breast cancer, oral squamous cell carcinoma, hepatocellular carcinoma,
multiple myeloma, and glioma [41]. Increased HSF1 expression has
been associated with a reduction in the survival rate and was proposed
as an independent prognostic factor for overall survival in patients with
estrogen receptor-positive breast cancer [33] and hepatocellular
carcinoma [8]. HSF1 could also change the sensitivity of cancer cells to
cytotoxic treatment [15,40]. However, the speciﬁc role of HSF1 activity
in malignant cells is not fully known. HSF1 is not a classical oncogene
or tumor suppressor but rather interfereswithmanymetabolic process-
es supporting tumor growth, which was called a “non-oncogene addic-
tion” [35]. It was previously shown that HSF1 activation diminishes cell
cycle checkpoints leading to aneuploidy [21] and inﬂuences RAS/MAPK
and cAMP/PKA signal transduction pathways essential for malignant
growth [7]. Furthermore, MEFs derived from Hsf1−/− animals were
unable to form colonies in soft agar [16] andwere deﬁcient inmigration
induced by basal and epidermal growth factors [28]. The motility of
bone marrow cells isolated from Hsf1−/− mice was also reduced [17].
The above-mentioned data suggests that HSF1 can affect the ability of
cells to migrate. A high migration potential is thought to be a prerequi-
site for tumor cell invasion and spread, hence suggesting the involve-
ment of HSF1 in the regulation of cancer metastasis. Importantly, HSF1
was found among six metastasis-promoting genes in malignant
melanomas [34]. Its ability to promote migration and invasion was
also observed in hepatocellular carcinomas [8]. Nevertheless, the exactthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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remains unclear.
In this study, we aimed to determine the role of HSF1 in tumor
growth and in the ability of cells to migrate. Melanoma cell lines
(mouse B16F10 and humanWM793B and 1205Lu)withmodiﬁed levels
of HSF1 activity were established and tested for different migration-
related processes. We found that active HSF1 can support cell motility
via amechanismmediated by down-regulation of vinculin and an inﬂu-
ence on the actin cytoskeleton organization.
2. Materials and methods
2.1. Experimental model
Melanoma cell lines: B16F10, WM793B and 1205Luwere purchased
from the American Type Cell Culture Collection (ATCC, Manassas, VA).
Cell culture and heat shock treatment were performed as described in
details elsewhere [40].
2.2. DNA constructs and transfections
The aHSF1 (hHSF1ΔRD) construct, containing the active form of
human HSF1 (with deletion of amino acid 221–315) driven by the
human β-actin promoter, was kindly provided by Dr. A. Nakai [26].
The aHSF1 sequence was re-cloned into the pLNCX2 retrovirus expres-
sion vector (Clontech) downstream of the CMV promoter [14]. The tar-
get sequences for knock-down of mouse Hsf1 gene were as follows:
HSF1-1 (1856–1876, NM_008296.2)—5′ GCTGCATACCTGCTGCCTTTA;
and HSF1-2 (341–359, NM_008296.2)—5′AGCACAACAACATGGCTAG.
Stably transfected B16F10, WM793B and 1205Lu cells were obtained
as described in details elsewhere [40].
2.3. Thermotolerance test
Logarithmically growing cells were thermally preconditioned by
placing them in a water bath at a temperature of 42 °C for 1 h, then
cells were allowed to recover in a CO2 incubator at 37 °C for 6 h before
a subsequent severe heat shock (1 h at 45 °C for B16F10 cells, 1 h at
48 °C for 1205Lu cells, or 30 min at 49 °C for WM793B cells). Alterna-
tively, cellswere subjected to a severe heat shockwithout precondition-
ing (condition of severe heat stress was established experimentally to
achieve a cell survival rate which was higher than 50%). After heat
shock cells were allowed to recover at 37 °C for 18 h, then harvested,
stainedwith propidium iodide and analyzed on a FACS Canto cytometer
(Becton Dickinson). Cell survival rate was calculated in relation to
untreated controls; all experiments were performed in triplicate at least.
2.4. Proliferation test
Cells (2 × 104 cells per well) were seeded and cultured in 12-well
plates. At the indicated time cells were washed with PBS, ﬁxed in cold
methanol, and rinsed with distilled water. Cells were stained with
0.1% crystal violet for 30 min, rinsed with distilled water extensively,
and dried. Cell-associated dye was extracted with 1 ml of 10% acetic
acid. Aliquots (200 μl) were transferred to a 96-well plate and the
absorbance was measured at 595 nm (Synergy2, BioTek). Values were
normalized to the optical density on day 0; all experiments were
performed in triplicate at least.
2.5. Anchorage-independent growth
B16F10 cells (2 × 103 perwell, in 1ml of growthmedium containing
0.35% noble agar, Difco, Becton Dickinson)were seeded on top of a solid
growthmedium containing 1%noble agar (1ml) in a 12-well plate. Cells
were covered with 300 μl of growthmedium, whichwas supplementedevery 3 days. After 21 days colonieswere stainedwith 0.1% crystal violet
and counted. All experiments were performed in triplicate at least.
2.6. Trans-well migration test (Boyden Chamber Assay)
Transwell chambers (with 8-μm pore size membrane, Becton Dick-
inson) were coated with ﬁbronectin (10 μg/ml, Becton Dickinson).
Cells (5 × 104 of B16F10 or 1205Lu, and 2.5 × 104 of WM793B) were
suspended in a Hepes-buffered serum-free medium containing 0.1%
BSA, seeded in the top of the chambers, and placed in thewells contain-
ing medium supplemented with 10% fetal bovine serum. After 4 h
(B16F10 and 1205Lu) or 2 h (WM793B) the inserts were washed with
PBS, ﬁxed with cold methanol, rinsed with distilled water, and stained
with 0.1% crystal violet for 30 min. The cells on the upper surface of
the insertswere gently removedwith a cotton swab. Cells thatmigrated
onto the lower surfacewere counted under amicroscope inﬁve random
ﬁelds; all experiments were performed in triplicate at least.
2.7. In vivo animal experiments
B16F10 cells (2× 105 cells permouse)were injected subcutaneously
into 6–8-week-old C57BL/6 females (experimental group n = 6).
Tumor growth was evaluated daily (for 8 days starting from tumor
size ~10 mm3) by caliper measurement in two perpendicular dimen-
sions. Tumor volume was calculated using the formula: volume
(mm3) = 0.52 × (width)2 × length [44]. To study the ability of
B16F10 cells to metastasize, cells (2 × 105 cells per mouse) were
injected into the tail vein (experimental group n= 10). Ten days after
injection, mice were sacriﬁced by cervical dislocation. The lungs were
collected and ﬁxed in Bouin's solution. Metastasis foci were counted.
All animal procedures were conducted in accordance with the recom-
mendation of the Polish Council on Animal Care and were approved
by the Local Committee of Ethics and Animal Experimentation at the
Medical University of Silesia in Katowice, Poland (Decision No 77/
2008 and 42/2012). The animals were maintained under controlled en-
vironmental conditions with a 1:1 light:darkness cycle, and were pro-
vided with unrestricted access to food and tap water.
2.8. Ki-67 index
Ki-67 immunostaining with polyclonal anti-rabbit antibody
(1:1000; ab66155, Abcam) was performed on 5 μm-sections of
paraformaldehyde-ﬁxed (4% in PBS, overnight at 4 °C) and parafﬁn-
embedded B16F10 tumors. An antigen retrieval step in 0.01 M citrate
buffer pH 6.0 was performed before the immunohistochemistry proce-
dure. An ImmPRESS Anti-Rabbit Ig (peroxidase) Polymer Detection
Kit (Vector Labs, Burlingame, CA, USA) was used according to the
manufacturer's guideline. DAB (3′,5′-diaminobenzidine) was used as a
chromogen for visualization of immunohistochemical reactions and he-
matoxylin was used for nuclei counterstaining. Negative controls for
speciﬁcity of the stainingwere performed by omitting the primary anti-
body. The Ki-67 index was determined by manual counting of N2000
cells from each section and shown as the relative number of nuclei
showing positive staining.
2.9. RT2 Proﬁler PCR array and quantitative RT-PCR
Expression of motility-related genes was assessed using the Mouse
Cell Motility RT2 Proﬁler PCR Array (SABiosciences, Frederick, USA).
Total mRNA was isolated using a RNeasy kit (Qiagen) and converted
into cDNA using a RT2 First Strand Kit (SABiosciences, Frederick, USA).
The cDNA was added to the RT2 SYBR Green qPCR Master Mix
(SABiosciences, Frederick, USA) and aliquotted on theMouse Cell Motil-
ity PCR arrays. All steps, including analysis of PCR data, were carried out
according to the manufacturer's protocol using the CFX96TM Bio-Rad
Real-time System. Gene-speciﬁc quantitative RT-PCR was performed
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and reverse primers (5 pmoles each) and cDNA template were added
to Real-Time 2x PCR Master Mix SYBR A (A&A Biotechnology, Gdynia,
Poland). Reactionswere incubated at 95 °C for 3min, followed by 40 cy-
cles of 95 °C for 30 s, 58 °C for 30 s and 72 °C for 30 s. Analyzed genes
were normalized againstGAPDH. Primer characteristics used in analyses
are presented in Suppl. Table 1.
2.10. Western blotting
Cellular proteins were extracted using a RIPA (Radio-Immunopre-
cipitation Assay) buffer, separated on 8–12% SDS-PAGE gels and
electrotransferred onto a PVDF membrane (Merck Millipore). Primary
antibodies used were: HSF1 (1:1000, ADI-SPA-901, Enzo Life Sciences),
vinculin (1:1000, 05-386, Millipore), actin (1:3000, MAB1501,
Millipore), HSC70/HSPA8 (1:3000, sc-7298, Santa Cruz Biotechnology),
and antibodies from the EMTAntibody Sampler Kit (1:1000, #9782, Cell
Signaling Technology). The primary antibodywas detected by an appro-
priate secondary antibody conjugated with horseradish peroxidase
(ThermoScientiﬁc), and visualized by an ECL (enhanced chemilumines-
cence) kit (ThermoScientiﬁc). When indicated, changes in the level of
expressionwere estimated by protein bands densitometry using ImageJ
software after normalization against loading controls (HSPA8 or actin).
2.11. Chromatin immunoprecipitation
Control cells (with the empty Neo vector) and cells expressing active
HSF1 were trypsinized and suspended in 10 ml of CO2 saturated media.
For positiveHSF1-binding probe, control (Neo) cells were heat shocked:
an equal volume, pre-heated to 55 °C medium was added to the cell
suspension, which immediately raised the temperature of the medium
from 37 °C to 43 °C. The tube was submerged in a water bath at the 43
°C for an additional 15min. Cells were ﬁxed and the ChIP assay was car-
ried out according to the protocol of ChIP kit of Upstate Biotechnology
(Lake Placid, NY) using protein A-sepharose beads (Amersham). For
30 μg of chromatin sonicated to 100–500 bp fragments, 3 μg of rabbit
anti-HSF1 (cat. noADI-SPA-901, Enzo Life Sciences) polyclonal antibody
was used. For ChIP negative controls chromatin sampleswere processed
without antibody (mock IP). Immunoprecipitated DNAwas dissolved in
20 μl of H2O and analyzed by PCR (ChIP-PCR) using primers comple-
mentary to the Hsph1/HSPH1 promoter (positive control of HSF1 bind-
ing) or to the Vcl/VCL gene sequences. For each reaction, 1 μl of the
template was used and 40 PCR cycles were applied. In “Input” sample,
0.003–0.006% of the total material used in the ChIP assay served as the
template for PCR. Primer characteristics used in analyses are presented
in Suppl. Table 1.
2.12. Cell adhesion assay
96-well plates were coated overnight with 20 μg/ml of ﬁbronectin
(BectonDickinson), and then blockedwith BSA in a serum-freemedium
(rinsed twice with 0.1% BSA, blocked with 0.5% BSA for 60 min at 37 °C
in a 5% CO2 incubator then rinsedwith 0.1% BSA). Cells (2 × 104 perwell
in 50 μl of medium with 10% of fetal bovine serum) were seeded into
ﬁbronectin/BSA-coated wells and into wells coated only with BSA
(negative control), then allowed to attach for 30 min or 7 h. At the
end of the experiment not adhered cells were removed by washing
twice with serum-free medium containing 0.1% BSA and attached cells
were ﬁxed in 4% PFA for 10 min, and then stained with 0.1% crystal vio-
let for 30min, washedwithwater and air dried. Cell-associated dyewas
extracted with 200 μl of 10% acetic acid and absorbance was measured
at 595 nm(Synergy2, BioTek). Relative adherence of cellswas estimated
as absorbance of cells adhered after 30 min vs. absorbance of cells ad-
hered after 7 h (positive control), then percentage of cells adhered to
BSA-coated cells was subtracted from values obtained in ﬁbronectin-coated wells. All experiments were repeated four times at least; each
repetition was represented by 8–12 wells.
2.13. Immunocytochemistry
Cells (5 × 104 per well) were seeded on 4-well glass slides (Nunc)
coated with ﬁbronectin (20 μg/ml, Becton Dickinson) and allowed to
grow for 4 h. Then cells were brieﬂy washed with PBS, ﬁxed with 4%
paraformaldehyde for 10 min, and permeabilized with 0.1% Triton-
X100. After blocking with 2.5% normal goat serum, slides were incubat-
ed with an antibody against vinculin (1:100, 05-386, Millipore) at 4 °C
overnight. The primary antibody was detected with a ﬂuorescein
isothiocyanate-conjugated secondary antibody (1:200, Sigma-
Aldrich). Filamentous actin was visualized by incubation with
tetramethylrhodamine B-conjugated phalloidin (1:800, Sigma-
Aldrich), while nuclei were counterstained with DAPI (Sigma-Aldrich).
Slides were mounted in a DAKO ﬂuorescent medium (Dako), and ana-
lyzed under an Axioimager M2 microscope (Carl Zeiss, Germany)
using a 63 X Plan Neoﬂuar oil objective (NA = 1.25). Each experiment
was performed in duplicate; approximately 200 cells were counted
manually in randomly chosen ﬁelds for each duplicate.
2.14. Statistical analysis
For each dataset the normality of distribution was assessed by the
Jarque–Bera test and homogeneity of variances was veriﬁed by the F−
or Bartlett's tests depending on the subgroup number to provide
optimal tools for statistical analysis; moreover, single outliers were iden-
tiﬁed by Dixon's test, while multiple outliers—by the Iglewicz–Hoaglin
test. For analysis of differences between compared groups the quality
of mean values was veriﬁed by the ANOVA test with pairwise compari-
son done with Dunnett's test. In case of non-Gaussian distribution, the
Kruskal–Wallis ANOVAwas applied for the veriﬁcation of the hypothesis
on the equality of medians with Dunn's test for pairwise comparisons.
P= 0.05 was selected as a statistical signiﬁcance threshold.
3. Results
3.1. Validation of the experimental model—expression of active HSF1 in
melanoma cells is sufﬁcient to develop thermotolerance
To mimic conditions of HSF1 activation in the absence of hyperther-
mia we established mouse (B16F10) and human (WM793B and
1205Lu) melanoma cells that over-expressed a constitutively-active
transcriptionally-competent form of HSF1 (aHSF1) (Fig. 1A). In addi-
tion, we constructed B16F10 cells with silenced expression of HSF1
(using two different shRNAs: shHSF1-1 targeting 3′UTR, and shHSF1-2
targeting coding sequence). We have previously documented [40] that
the aHSF1 could be effectively expressed in both mouse and human
melanoma cells, which is accompanied with an increased expression
of several inducible HSPs (HSPH1, HSPA1, HSPB1) already at physiolog-
ical conditions (i.e. in the absence of hyperthermia). Furthermore, both
HSF1-speciﬁc RNAi sequences diminished the Hsf1 mRNA level,
which was associated with the reduction of endogenous HSF1 protein
level in B16F10 cells (Fig. 1A) and consecutive suppression of
hyperthermia-inducible expression of Hsph1, Hsp90aa1, Hspa1, and
Hspb1 genes (shHSF1-1 targeting 3′UTR was more effective) [40].
To address the functional signiﬁcance of active HSF1 level we
assessed the survival of cells exposed to heat shock. Direct exposure of
wild type cells (unmodiﬁed) or cells transfected with the empty
vectors to severe heat shock (above 45 °C) caused a substantial reduc-
tion of cell survival in comparison to untreated control. Thermal precon-
ditioning of such cells at the sublethal temperature (42 °C) resulted in a
signiﬁcant level of thermotolerance that protected them from subse-
quent severe heat stress. In contrast, the aHSF1-expressing cells ex-
posed directly to severe heat shock showed a survival rate comparable
Fig. 1. Thermotolerance of mouse and human melanoma cells with different status of
HSF1. (A)Western blot detection of HSF1 in B16F10,WM793B, and 1205Lu cells. Viability
of mouse (B) and human (C) cells in different thermal conditions. The number of viable
cells is depicted in relation to heat-untreated cells (100%). Untreated control—culture at
37 °C, HS—exposure to severe heat shock (above 45 °C); PC+ HS—thermal precondition-
ing at 42 °C prior to severe heat shock. Cell description:WT—wild type, unmodiﬁed cells;
Neo—control cells with the empty vector; aHSF1—cells over-expressing aHSF1; scr., HSF1-
1, and HSF1-2—cells transfected with scramble shRNA, HSF1-1, and HSF1-2, respectively.
Themean values and±SD from at least three experiments are shown; asterisks represent
p-values ≤0.05).
Fig. 2. Proliferation indices in B16F10 cells with different HSF1 status. (A) Cell growth
in vitro (assessment based on crystal violet staining). (B) Volume of B16F10 tumors
in vivo. (C) Ki-67 index in B16F10 tumors in vivo. The mean values and ±SD from at
least three experiments are shown; an asterisk indicates p b 0.05. The description of
cells is the same as in the Fig. 1 legend.
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further increased the survival rate of such cells). The same result was
observed for all three cell lines expressing aHSF1 (Fig. 1). Furthermore,
B16F10 cells with silenced HSF1 were more sensitive to severe heat
shock than wild type cells; the effect was stronger in the case of
shHSF1-1 (Fig. 1B), which was more effective in silencing HSF1-
dependent genes [40]. Thus, we have conﬁrmed that the development
of thermotolerance in melanoma cells depends on the activity of HSF1.
We have also concluded that aHSF1 is able to regulate HSPs expression
at a level sufﬁcient to drive a thermotolerant phenotype; hence
expression of aHSF1 in mouse and human melanoma cells mimics the
conditions of HSF1 activation.
3.2. Expression of active HSF1 supports motility, anchorage-independent
growth, and in vivo metastasis potential of melanoma cells
To assess the role of HSF1 in tumor growth we compared the prolif-
eration rate of control B16F10 cells with a normal level of endogenous
HSF1 (i.e., unmodiﬁed/wild type, or controls with the empty Neo vectoror scramble shRNA) and cells with experimentally modiﬁed HSF1 level
(i.e., with an over-expression of aHSF1 or HSF1 silenced by shRNA). We
found that neither over-expression of aHSF1 nor silencing of endoge-
nous HSF1 inﬂuenced the rate of cell proliferation in vitro and up to
72 h of culture no substantial differences between the tested cell lines
were observed (Fig. 2A); the only exceptionwas a slightly slower prolif-
eration observed after 72 h in the case of shHSF1-2 silenced cells (p=
0.023). Similarly, neither expression of aHSF1 nor silencing of HSF1
affected cell proliferation in vivo—no signiﬁcant differences in the
growth of primary in situ tumors derived from B16F10 cells with a
different HSF1 status injected subcutaneously into C57BL/6 mice were
observed (Fig. 2B). Finally, we did not observe any signiﬁcant differ-
ences in the pattern of Ki-67proliferationmarker between these tumors
(Fig. 2C). We have concluded that neither activation nor inhibition of
HSF1 inﬂuences the proliferation rate of B16F10mousemelanoma cells.
In the next stepwe tested the inﬂuence of HSF1 status on themigra-
tion ability of B16F10 cells. We found that cells with over-expression of
aHSF1 grow signiﬁcantly faster in soft agar (anchorage-independent
growth). Cells expressing aHSF1 generated two times more colonies
(p b 0.0001; ANOVA test; Fig. 3A), and the colonies weremarkedly larg-
er compared to control cells. However, the silencing of HSF1 did not
affect the growth of cells in soft agar. Additionally, we tested the
in vitro motility of cells using the Boyden chamber assay. We found
Fig. 3.Motility of cells with different HSF1 status. Anchorage independent growth in soft agar (A), migration in the trans-well chamber system (B), and the number of lung metastases
in vitro (ten day after iv injection) (C) assessed for B16F10 cells with different HSF1 status. (D)Migration ofWM793B and 1205Lu cells in the trans-well chamber system. Themean values
and ± SD from at least three experiments are shown; asterisks indicate p b 0.05. The description of cells is the same as in the Fig. 1 legend.
Fig. 4. Expression of the EMT markers in cells with different HSF1 status. Representative
western blot analysis in B16F10,WM793B, and 1205Lu cells. HSPA8was used as a loading
control. The description of cells is the same as in the Fig. 1 legend.
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creased the potency of cells to migrate into the lower compartment of
the chamber containing a medium with serum (Fig. 3B), yet silencing
of HSF1 did not affect signiﬁcantly this phenotype. Finally, we assessed
the in vivometastasis potential of B16F10 cells after their injection into
the tail vein of C57BL/6mice. The injection of cells with over-expression
of aHSF1 led to the formation of a signiﬁcantly higher number of lung
metastases compared to mice injected with control cells (p b 0.0001;
ANOVA test). Furthermore, the injection of cells with silenced HSF1
could result in a reduced number of lung metastases (the effect
observed for line with HSF1-2 shRNA; p = 0.019) (Fig. 3C). We have
concluded that the presence of active HSF1 supports the motility and
metastatic potential of B16F10 mouse melanoma cells.
We tested also the ability of active HSF1 to support the motility of
human WM793B and 1205Lu melanoma cell lines. We found that
control WM793B cells showed a very high migration potential (in the
Boyden chamber assay), which was barely enhanced by aHSF1 expres-
sion. Inmarked contrast, control 1205Lu cells showed a lowermigration
potential, which was signiﬁcantly enhanced (p = 0.0016) in cells
expressing aHSF1, resembling the effect observed in B16F10 cells
(Fig. 3D). It should be noted that WM793B cells are of a pre-
metastatic type and were established from the primary melanoma of a
vertical growth phase, while 1205Lu cells are of a metastatic type and
were derived from the lung metastases of WM793B cells. It is notewor-
thy, that in none of tested melanoma cell lines the expression of aHSF1
affected the ability to migrate in the scratch-wound assay (not shown).
3.3. Expression of active HSF1 reduces the level of vinculin
Increased cell migration is an in vitro functional marker of the
epithelial to mesenchymal transition (EMT) [20], which frequently
accompanies tumor progression and metastatic process. Knowing that
expression of aHSF1 enhances migration potential we aimed to
determine whether the status of HSF1 affects levels of EMT-associated
proteins. We analyzed by Western blot levels of several EMT markers,
including N-cadherin, E-cadherin, ZEB1, vimentin, catenin beta-1,
SNAI1 (Snail1), SNAI2 (Slug), and claudin-1 (Fig. 4). None of the tested
cell lines expressed E-cadherin (marker of epithelial cells) and claudin-
1 (not shown), while N-cadherin was lacking in 1205Lu cells (derived
from metastasis). Expression of SNAI1 and SNAI2 (which was notdetected in B16F10 cells) was slightly decreased in WM793B and
1205Lu cells expressing aHSF1. However, other analyzed EMT markers
were expressed at comparable levels irrespective of the HSF1 status in
all cell lines. We have concluded that the HSF1-dependent enhance-
ment of cell migration is not related to EMT up-regulation.
To further our search for possible migration-related factors targeted
by HSF1,we used theMouse Cell Motility RT2 Proﬁler PCRArray to com-
pare the expression ofmotility-related genes in control B16F10 cells and
in cells over-expressing aHSF1. Among 84 analyzed genes we did not
ﬁnd any gene up-regulated due to the expression of aHSF1. However,
the expression of several genes, namely Vcl, Ptk2b, Cav1, Capn1, and
Mmp2, was signiﬁcantly down-regulated (p b 0.05) in cells expressing
aHSF1 (Fig. 5A). Human WM793B and 1205Lu cells over-expressing
aHSF1 also showed a signiﬁcant down-regulated level (p b 0.05) of
VCL gene transcripts compared to control cells (Fig. 5B). In further stud-
ies we focused on the Vcl gene because at the protein level a signiﬁcant
down-regulation was observed only for vinculin when B16F10 cells
expressing active HSF1 were analyzed. Moreover, a slightly increased
Fig. 5. Expression of vinculin in cells with different HSF1 status. Quantitative RT-PCR evaluation ofmRNA level of motility-related genes in B16F10 cells (A) and VCL gene inWM793B and
1205Lu cells (B); shown are transcript levels in cells over-expressing aHSF1 in relation to Neo controls (for all differences p-value≤0.05). (C)Western blot detection of vinculin and focal
adhesion kinase (PTK2); actinwasused as a loading control (shown are representative blots from three experiments). Numbers belowblots represent protein ratios in relation to adequate
controls (based on densitometry of three experimental repetitions, after normalization against actin). (D) Binding of HSF1 in the ﬁrst exon and the second intron of Vcl/VCL gene analyzed
by ChIP-PCR. Hsph1/HSPH1 promoter was used as positive control for HSF1 binding. Mock IP—control reaction without Ab,−/+—negative and positive PCR control (without template/
genomic DNA template). The description of cells is the same as in the Fig. 1 legend.
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pression of HSF1 (linewith HSF1-1 shRNA) (Fig. 5C). The level of vincu-
lin proteinwas also down-regulated in 1205Lu cells but not inWM793B
cells (Fig. 5C), which suggests an additional post-transcriptional mech-
anism of regulation inWM793B cells. TheVCL gene contains severalHSE
motifs, which indicates the possible involvement of HSF1 in the gene
regulation. Based on data of the HSF1 genome-wide binding assessed
by ChIP-Seq in heat shocked U2OS cells (not published)we have chosen
the potential HSF1 binding sites to be analyzed inmelanoma cells. To di-
rectly conﬁrm involvement of HSF1 in the regulation of the Vcl/VCL
gene, an actual binding of HSF1 was assessed using ChIP assay. As
expected, we found enhanced HSF1 binding to the promoter of the
Hsph1/HSPH1 gene (which is a typical target of HSF1) both in heat
shocked cells and in cells expressing aHSF1 (Fig. 5D). In contrast, we
did not identify HSF1 binding in the Vcl/VCL promoter in anymelanoma
cell lines (not shown). On the other hand, in the human VCL gene HSF1
binding was detected in the second intron, both in 1205Lu and
WM793B cells. In the case of B16F10 cells binding of HSF1was detected
in the ﬁrst exon (in both heat shocked and aHSF1-expressing cells), yet
binding in the Vcl second intronwas not detected (in any of six checked
HSE-like motifs).
Most importantly, HSF1-mediated down-regulation of vinculin
corresponded to cell migration ability analyzed in vitro using the
Boyden chamber—in the same cells over-expression of aHSF1 resulted
in the down-regulation of vinculin and increased motility. We have
concluded that HSF1-dependent down-regulation of vinculin is associ-
ated with the enhanced ability to migrate in the case of B16F10 and
1205Lu cells.
3.4. Expression of active HSF1 affects the adhesion potential and the
structure of the cytoskeleton of melanoma cells
Vinculin is a membrane-cytoskeletal protein present in focal
adhesion plaques. Considering the HSF1-mediated down-regulation of
vinculin we compared the ability of cells with different HSF1 status to
adhere. The adhesion of cells to a ﬁbronectin-coated surface and to asurface coated with BSA (considered as a non-adhesive protein) was
compared. All tested cell lines adhered to ﬁbronectin more effectively
than to BSA: after the ﬁrst 30 min of incubation signiﬁcantly more
cells were attached to the surface coated with ﬁbronectin than to the
surface coated with BSA. Most importantly, the expression of aHSF1 re-
sulted in a reduced adhesion to ﬁbronectin in the case of B16F10 (p=
0.007) and 1205Lu (p= 0.17) cells, while it did not affect the adhesion
of WM793B cells (Fig. 6A). This result indicates an apparent association
between the down-regulation of vinculin, the reduced adhesion and the
enhanced motility of cells over-expressing active HSF1.
Considering interactions of vinculin with actin ﬁlaments [11] we an-
alyzed the inﬂuence of aHSF1 expression on a structure of an actin cyto-
skeleton of melanoma cells. B16F10 cells growing on a ﬁbronectin-
coated surfacewere stained using an anti-vinculin antibody to visualize
focal adhesion structures, and with ﬂuorescent phalloidin to visualize
actin ﬁlaments. We observed that the number of cells with focal adhe-
sion structures was signiﬁcantly reduced (p b 0.0001) in the population
of cells over-expressing aHSF1 (Fig. 6B). We classiﬁed cells into three
categories based on themorphology of the actin cytoskeleton: polarized
(motile cells with a clear lamellipodium and trailing edge), ambiguous
(multipolar cells with several lamellipodia), and not polarized (cells
without lamellipodia). The status of HSF1 apparently affected distribu-
tion of cells among such deﬁned categories: an underrepresentation of
cells with polarized morphology (p= 0.0006) and an overrepresenta-
tion of cells with not polarized morphology (p b 0.0001) were observed
in the population of cells over-expressing aHSF1 (Fig. 6C). This indicates
the inﬂuence of HSF1-mediated mechanisms on the structure of the
actin cytoskeleton of melanoma cells.
4. Discussion
HSF1 facilitates the malignant transformation and progression
of cancer, yet detailed mechanisms of its pro-metastatic activity
remain largely elusive. In the present work we used cells expressing a
constitutively-active transcriptionally-competent form of HSF1
(aHSF1) [14,26,39,40] to study the inﬂuence of HSF1 activation on
Fig. 6. Changes in adherence and morphology of cells with a different HSF1 status.
(A) Adhesion potential of B16F10, WM793B, and 1205Lu melanoma cells; shown is rela-
tive adherence of cells to ﬁbronectin-coated surface. (B) Focal adhesion (FA) structures
in B16F10 cells over-expressing aHSF1; shown is the relative number of cellswith focal ad-
hesion structures (left), as well as an example of FA+ and FA− cells (right). (C) Relative
numbers (left) and an example (right) of B16F10 cells with different morphologies:
polarized (P), ambiguous (A), not polarized (NP). Red—actin cytoskeleton, green—vinculin,
blue—nucleus. Scale bar—20 μm. Presented are mean values and ±SD from three experi-
ments; asterisks indicate p b 0.05.
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allowed a developing thermotolerance in melanoma cells, resembling
the function of endogenous heat-activated HSF1, which validated our
experimental model. It has been previously suggested that HSF1 can
support the growth of cancer cells [7]. However, we found that the ex-
pression of active HSF1 affects neither proliferation of melanoma cells
in vitro nor the growth of corresponding tumors in vivo. Nevertheless,
we found that the expression of active HSF1 enhanced the metastatic
potential of mousemelanoma cells in vivo. Among themechanisms crit-
ical for the formation of metastasis are cancer cell motility and
anchorage-independent growth. Most interestingly, we found that the
expression of active HSF1 affected both these features of cancer cells.
Mouse B16F10 and human 1205Lu melanoma cells expressing active
HSF1 acquired the enhanced migration ability when tested using the
Boyden chamber assay. Because we did not observe a signiﬁcant effect
of HSF1 status in scratch assays, we concluded that HSF1 putatively af-
fected chemotactic behavior. In the case of B16F10 cells we also found
the enhanced ability of cells expressing active HSF1 to grow in soft
agar (unattached to a surface). This indicates that the expression of ac-
tive HSF1 promotes a loss of the contact inhibition and the anchorage
independence, which are features of malignant transformation. Our ob-
servations were consistent with ﬁndings that down-regulation of HSF1
abrogated the ability of MEFs [28] or bone marrow cells [17] to migrate,
while HSF1 overexpression could promote the migration of hepatocellu-
lar carcinoma cells [8]. An association of HSF1 expression with a
metastatic potential was also described in prostate, hepatocellular, breast,
colon and lung tumors [8,10,13,23,36]. Furthermore, it has been recentlydemonstrated that silencingHSF1 suppressed themigration and the inva-
siveness of humanmelanomacells in vitro, and thatHSF1was required for
melanoma invasion and metastasis, as well as tumorigenic potential
in vivo [27]. All this data indicates collectively that HSF1 is involved in
the regulation of cell migration and metastasis formation, although the
speciﬁc mechanism of its action still remains unclear.
Cancer metastasis consists of several distinct steps, in which the
epithelial–mesenchymal transition (EMT) and the mesenchymal–
epithelial transition (MET) are critical events. The completion of the
EMT is characterized by an increased capacity for migration and three-
dimensional invasion [20]. It has been shown that hyperthermia
enhanced cell migration and the EMT plasticity in lung A549 adenocar-
cinoma, but such stress-induced plasticity and migration was HSF1-
independent [19]. Here we found that the expression of active HSF1
did not substantially affect the expression of several commonly used
markers of EMT. Hence, themechanism of HSF1-dependent stimulation
of cellmigration could be independent of EMT regulation. Cellmigration
is a complex process that integrates different protein–protein interac-
tions and signaling events, and includes focalized adhesion dynamics
and the remodeling of the structure of the actomyosin skeleton [9].
The potential role of HSPs and other chaperones in this process might
be considered because they are involved both in functions of cytoskele-
ton [22] and metastasis [4,25,38]. Hence, we can not exclude that
HSF1-regulated HSPs play a role in our experimental model. However,
we found here that the expression of active HSF1 resulted in the
down-regulation of several genes encoding for cytoskeleton proteins,
including vinculin, which markedly expanded the range of HSF1-
mediated mechanisms involved in metastasis. Vinculin localizes to
integrin-mediated cell–matrix adhesion and cadherin-mediated cell–
cell junction, and facilitates three-dimensional matrix invasion through
up-regulation or enhanced transmission of traction forces [24]. MEFs
deﬁcient in vinculin showed a lower potential to spread, smaller focal
adhesions and decreased strength of adhesion to ﬁbronectin, laminin,
vitronectin, and collagen, yet they migrated faster than their wild-type
counterparts [43]. Lack of vinculin expression in MEFs or low vinculin
expression in the mouse SV40 transformed 3T3 cells was associated
with a higher cell motility and a greater ability to grow in soft agar
[24,31,43]. Additionally, down-regulation of vinculin in mouse ovarian
cancer cells was associated with a reduced number of focal adhesion
and disorganized actin [6]. It was also reported that vinculin down-
regulation led to enhanced invasiveness of human prostate cancer
cells [5], and supported the cell motility of human colon adenocarcino-
ma Caco2 cells [12]. Hence, the level of vinculin is apparently associated
with the enhanced motility of cells.
We found that the presence of active HSF1 resulted in the transcrip-
tional down-regulation of vinculin. Furthermore, we evidenced actual
binding of HSF1 in HSE/HSE-like motifs present in Vcl/VCL genes down-
stream of the transcription start sites (i.e. ﬁrst exon or second intron). It
has been observed that the binding of the HSF1 outside promoter is fre-
quently associated with HSF1-mediated gene repression [23]. Hence,
our data suggests the direct involvement of activeHSF1 in transcription-
al down-regulation of vinculin. Most importantly, we observed appar-
ent association between HSF1-mediated down-regulation of vinculin,
increased motility and reduced adherence of cells. Notable results
were obtained with two closely related human melanoma cell lines:
WM793B cells with basically high migration potential that was barely
affected by active HSF1 and 1205Lu cells characterized by initially low
migration potential that was largely increased by active HSF1 (similar
to mouse B16F10 cells). Moreover, the expression of active HSF1 re-
duced the adherence of 1205Lu cells (similar to B16F10 cells), while ini-
tially the lower adherence of WM793B was not further reduced by
active HSF1. Additionally, we found an unchanged level of vinculin in
WM793B cells expressing active HSF1, in spite of the reduced level
of VCL transcript, which suggests hypothetical post-transcriptional
mechanisms of vinculin regulation in these cells (putatively not present
in B16F10 and 1205Lu cells).
401A. Toma-Jonik et al. / Cellular Signalling 27 (2015) 394–4015. Conclusions
We concluded that the activation of HSF1 apparently enhanced the
motility and metastatic potential of cancer cells, exempliﬁed here by
melanoma. Among potential HSF1-mediated mechanisms promoting
cell motility and invasiveness we found transcriptional down-regulation
of vinculin. Vinculin is a motility-related protein participating in the
dynamic reorganization of the cytoskeleton and apparently playing im-
portant roles in the regulation of cell migration. Hence, HSF1-dependent
down-regulation of vinculin offers a mechanistic explanation for HSF1-
mediated enhancement of motility and metastatic potential of cancer
cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2014.11.029.
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